Lv53
1210 积分 2020-05-26 加入
Gastroenterology/Hepatology: What You May Have Missed in 2024
6分钟前
已完结
The global, regional, and national burden of cancer, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023
8分钟前
已完结
Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy
3小时前
已完结
First Report of NSCLC With IDH1 Mutation: A Case Report
1天前
已完结
Urinary DNA Methylation Profiling Improves Discrimination of Prostate Cancer Across PSA-Defined Risk Strata
10天前
已关闭
Urinary DNA Methylation Test for Bladder Cancer Diagnosis
18天前
已关闭
Urinary DNA Methylation Test for Bladder Cancer Diagnosis
18天前
已完结
Tumour mutational burden: clinical utility, challenges and emerging improvements
28天前
已完结
Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti–PD-1 therapy: MASTERKEY-115
1个月前
已完结
Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti–PD-1 therapy: MASTERKEY-115
1个月前
已完结
皖公网安备34019202002308
